1,090
Views
1
CrossRef citations to date
0
Altmetric
Articles

Fiducial markers and their impact on ablation outcome for patients treated with MR-guided transurethral ablation (TULSA): a retrospective technical analysis

ORCID Icon, , , ORCID Icon, & ORCID Icon
Pages 1677-1684 | Received 12 Jul 2021, Accepted 12 Nov 2021, Published online: 20 Dec 2021

References

  • Wallis CJD, Saskin R, Choo R, et al. Surgery versus radiotherapy for clinically-localized prostate cancer : a systematic review and meta-analysis. Eur Urol. 2016;70(1):21–30.
  • O’neill AGM, Jain S, Hounsell AR, et al. Fiducial marker guided prostate radiotherapy: a review. Br J Radiol. 2016;89(1068):1–18.
  • Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and Castration-Resistant prostate cancer. Eur Urol. 2017;71(4):630–642.
  • Ingrosso G, Becherini C, Lancia A, et al. Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3(2):183–197.
  • Klotz L, Pavlovich CP, Chin J, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer. J Urol. 2021;205(3):769–779.
  • Lumiani A, Samun D, Sroka R, et al. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). Urol Oncol Semin Orig Invest. 2021;000:0–7.
  • Anttinen M, Mäkelä P, Viitala A, et al. Salvage magnetic resonance imaging-guided transurethral ultrasound ablation for localized radiorecurrent prostate cancer: 12-month functional and oncological results. Eur Urol Open Sci. 2020;22:79–87.
  • Burtnyk M, N’Djin WA, Kobelevskiy I, et al. 3D conformal MRI-controlled transurethral ultrasound prostate therapy: validation of numerical simulations and demonstration in tissue-mimicking gel phantoms. Phys Med Biol. 2010;55(22):6817–6839.
  • Georgiou PS, Jaros J, Payne H, et al. Beam distortion due to gold fiducial markers during salvage high-intensity focused ultrasound in the prostate. Med Phys. 2017;44(2):679–693.
  • Suomi V, Treeby B, Jaros J, et al. Transurethral ultrasound therapy of the prostate in the presence of calcifications: a simulation study. Med Phys. 2018;45(11):4793–4805.
  • Jonsson JH, Garpebring A, Karlsson MG, et al. Internal fiducial markers and susceptibility effects in MRI - simulation and measurement of spatial accuracy. Int J Radiat Oncol Biol Phys. 2012;82(5):1612–1618.
  • Tatebe K, Ramsay E, Mougenot C, et al. Influence of geometric and material properties on artifacts generated by interventional MRI devices: relevance to PRF-shift thermometry. Med Phys. 2016;43(1):241–253.
  • Schenck JF. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Med Phys. 1996;23(6):815–850.
  • Mougenot C, Moonen C. Magnetic resonance-guided high intensity focused ultrasound in the presence of biopsy markers. J Ther Ultrasound. 2017;5(1):1–11.
  • Bakaric M, Martin E, Georgiou PS, et al. Experimental study of beam distortion due to fiducial markers during salvage HIFU in the prostate. J Ther Ultrasound. 2018;6(1):1–11.
  • Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787–800.
  • Jansen BHE, van Leeuwen PJ, Wondergem M, et al. Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the phoenix criteria for biochemical recurrence after curative radiotherapy. Eur Urol Oncol. 2021;4(5):821–825.
  • Hellinger JC, Blacksberg S, Haas J, et al. Interventional uroradiology in the management of prostate cancer. Appl Radiol. 2015;44(9):40–41.
  • Anttinen M, Mäkelä P, Suomi V, et al. Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. Scand J Urol. 2019;53(5):295–302.
  • Maspero M, Seevinck PR, Willems NJW, et al. Evaluation of gold fiducial marker manual localisation for magnetic resonance-only prostate radiotherapy. Radiat Oncol. 2018;13(1):105.
  • Fütterer JJ, Moche M, Busse H, et al. In-bore MR-guided biopsy systems and utility of PI-RADS. Top Magn Reson Imaging. 2016;25(3):119–123.
  • Zhu M, Sun Z, Ng CK. Image-guided thermal ablation with MR-based thermometry. Quant Imaging Med Surg. 2017;7(3):356–368.
  • Chaussy CG, Thüroff S. High-Intensity focused ultrasound for the treatment of prostate cancer: a review. J Endourol. 2017;31(S1):S30–S37.
  • Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802–8813.
  • Persaud S, Sofat S, Lacey N, et al. Signal voids created by prostatic urethral lift implants – a reminder in the era of multiparametric MRIs of the prostate. Int J Med Rev Case Rep. 2019;3:426.